Atherosclerosis imaging in statin intervention trials

QJM: An International Journal of Medicine

Volumn 100, Issue 5, 2007, Pages 253-262

  Yanai, H ^a,c   Yoshida, H ^a   Tomono, Y ^b   Tada, N ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JOSAI UNIVERSITY   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COLESTYRAMINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; PROBUCOL; SIMVASTATIN;

ARTERY DISEASE; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; B SCAN; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIET THERAPY; DRUG DOSE COMPARISON; HUMAN; HYPERLIPIDEMIA; MEDLINE; MONOTHERAPY; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PULSE RATE; REVIEW;

EID: 34447337743     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm025     Document Type: Review

References (96)

1. Karnik R. The value of lipid lowering in patients with coronary heart disease. J Clin Basic Cardiol 2001; 4:31-4.
2. Scandinavian Simvastatin Survival Study Group.Randomized trials of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Survival Study (4S). Lancet 1994;344:1383-9.
3. The long-term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-57.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-7.
6. Morasch MD. New diagnostic imaging techniques. Perspect Vasc Surg Endovasc Ther 2005; 17:341-50.
7. Berman DS, Hachamovitch R, Shaw LJ, Friedman JD, Hayes SW, Thomson LE, Fieno DS, Germano G, Wong ND, Kang X, Rozanski A. Roles of nuclear cardiology, cardiac computed tomography, and cardiac magnetic resonance: Noninvasive risk stratification and a conceptual framework for the selection of noninvasive imaging tests in patients with known or suspected coronary artery disease. J Nucl Med 2006; 47 1107-18.
8. Berman DS, Hachamovitch R, Shaw LJ, Friedman JD, Hayes SW, Thomson LE, Fieno DS, Germano G, Slomka P, Wong ND, Kang X, Rozanski A. Roles of Nuclear Cardiology, Cardiac Computed Tomography, and Cardiac Magnetic Resonance: Assessment of Patients with Suspected Coronary Artery Disease. J Nucl Med 2006; 47:74-82.
9. Raggi P, Taylor A, Fayad Z, O'Leary D, Nissen S, Rader D, Shaw LJ. Atherosclerotic plaque imaging: Contemporary role in preventive cardiology. Arch Intern Med 2005; 165:2345-53.
10. da Luz PL, Bertini PJ, Favarato D. Noninvasive detection of coronary artery disease - challenges for prevention of disease and clinical events. Clinics 2005; 60:415-28.
11. Fuster V, Fayad ZA, Moreno PR, Poon M, Corti R, Badimon JJ. AthArothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol 2005; 46:1209-18.
12. Rajaram V, Pandhya S, Patel S, Meyer PM, Goldin M, Feinstein MJ, Neems R, Liebson PR, Fiedler BM, Macioch JE, Feinstein SB. Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy. Am J Cardiol 2004; 93:32-48C.
13. Patel SN, Rajaram V, Pandya S, Fiedler BM, Bai CJ, Neems R, Feinstein M, Goldin M, Feinstein SB. Emerging, noninvasive surrogate markers of atherosclerosis. Curr Atheroscler Rep 2004; 6:60-8.
14. Jacoby DS, Mohler III ER, Rader DJ. Noninvasive atherosclerosis imaging for predicting cardiovascular events and assessing therapeutic interventions. Curr Atheroscler Rep 2004; 6:20-6.
15. Bisoendial RJ, Hovingh GK, de Groot E, Kastelein JJ, Lansberg PJ, Stroes ES. Measurement of subclinical atherosclerosis: Beyond risk factor assessment. Curr Opin Lipidol 2002; 13:595-603.
16. Feinstein SB, Voci P, Pizzuto F. Noninvasive surrogate markers of atherosclerosis. Am J Cardiol 2002; 89:31-43C.
17. Maroo A, O'Donnell CJ. Current practice and future promise for clinical noninvasive measurements of subclinical atherosclerotic disease in the elderly. Am J Geriatr Cardiol 2002; 11:108-16.
18. Pearson TA. New tools for coronary risk assessment: What are their advantages and limitations? Circulation 2002; 105:886-92.
19. Kates AM, Vedala G, Woodard PK, Davila-Roman VG, Gropler RJ. Noninvasive coronary artery imaging in the diagnosis and management of patients with ischemic heart disease. Curr Opin Cardiol 1999; 14:314-20.
20. Vallabhajosula S, Fuster V. Atherosclerosis: Imaging techniques and the evolving role of nuclear medicine. J Nucl Med 1997; 38 1788-96.
21. Ayers CR. New diagnostic inroads in hypertension and atherosclerosis. Curr Opin Cardiol 1995; 10:480-4.
22. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res 2001; 89:305-16.
23. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P; European Lacidipine Study on Atherosclerosis investigators.Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106:2422-7.
24. Wikstrand J, Berglund G, Hedblad B, Hulthe J. Antiatherosclerotic effects of beta-blockers. Am J Cardiol 2003; 91:25-9.
25. Paliotti R, Ciulla MM, Hennig M, Tang R, Bond MG, Mancia G, Magrini F, Zanchetti A. Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: An echoreflectivity study. J Hypertens 2005; 23:1203-9.
26. Tomas JP, Moya JL, Barrios V, Campuzano R, Guzman G, Megias A, Ruiz-Leria S, Catalan P, Marfil T, Tarancon B, Muriel A, Garcia-Lledo A. Effect of candesartan on coronary flow reserve in patients with systemic hypertension. J Hypertens 2006; 24:2109-14.
27. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S; Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348:2294-303.
28. Kim SH, Lee SJ, Kang ES, Kang S, Hur KY, Lee HJ, Ahn CW, Cha BS, Yoo JS, Lee HC. Effects of lifestyle modification on metabolic parameters and carotid intima-media thickness in patients with type 2 diabetes mellitus. Metabolism 2006; 55:1053-9.
29. Yamasaki Y, Katakami N, Hayaishi-Okano R, Matsuhisa M, Kajimoto Y, Kosugi K, Hatano M, Hori M. alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract 2005; 67:204-10.
30. Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 2005; 46:63-7.
31. Hjerkinn EM, Abdelnoor M, Breivik L, Bergengen L, Ellingsen I, Seljeflot I, Aase O, Ole Klemsdal T, Hjermann I, Arnesen H. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil 2006; 13:325-33.
32. Sawayama Y, Maeda S, Ohnishi H, Okada K, Hayashi J. Effect of probucol on elderly hypercholesterolemic patients in the FAST study. Fukuoka Igaku Zasshi 2006; 97:15-24.
33. Spacil J, Spacabilova J. The ankle-brachial blood pressure index as a risk indicator of generalized atherosclerosis. Semin Vasc Med 2002; 2:441-5.
34. Leng GC, Fowkes FGR, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: A cohort study. BMJ 1996; 13:1440-4.
35. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286:1317-24.
36. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005; 19:103-9.
37. Grodzinska L, Starzyk D, Bieron K, Goszcz A, Korbut R. Simvastatin effects in normo- and hypercholsterolemic patients with peripheral arterial occlusive disease: A pilot study. Basic Clin Pharmacol Toxicol 2005; 96:413-19.
38. Koji Y, Tomiyama H, Ichihashi H, Nagae T, Tanaka N, Takazawa K, Ishimaru S, Yamashina A. Comparison of ankle-brachial pressure index and pulse wave velocity as markers of the presence of coronary artery disease in subjects with a high risk of atherosclerotic cardiovascular disease. Am J Cardiol 2004; 94:868-72.
39. Shinohara K, Shoji T, Kimoto E, Yokoyama H, Fujiwara S, Hatsuda S, Maeno T, Shoji T, Fukumoto S, Emoto M, Koyama H, Nishizawa Y. Effects of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2005; 12:205-10.
40. Muramatsu J, Kobayashi A, Hasegawa N, Yokouchi S. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. Atherosclerosis 1997; 130:179-82.
41. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: A preliminary study. J Hum Hypertens 2002; 16:705-10.
42. Yamashina A, Tomiyama H, Arai T, Hirose K, Koji Y, Hirayama Y, Yamamoto Y, Hori S. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003; 26:615-22.
43. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 1997; 146:483-94.
44. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, Rosamond WD, Evans G. Carotid wall thickness is predictive of incident clinical stroke: The Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151:478-87.
45. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Bruke BL, Wolfson SK Jr. Cardiovascular Health Study Collaborative Research Group. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340:14-22.
46. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid artery intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997; 96:1432-7.
47. Furberg CD, Adams HP, Jr, Applegate WB, et al. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90:1679-87.
48. de Groot E, Jukema JW, van Boven AJ, Reiber JH, Zwinderman AH, Lie KI, Ackerstaff RA, Bruschke AV. Effects of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: A report form the Regression Growth Evaluation Statin Study. Am J Cardiol 1995; 76:40-6.
49. Byington RP, Furberg CD, Crouse JR 3rd, Espeland MA, Bond MG. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 76:54-9.
50. Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT. Kuopio Atherosclerosis Prevention Study (KAPS): A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92:1758-64.
51. Wendelhag I, Wiklund O, Wikstrand J. Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral artery. Atherosclerosis 1995; 117:225-36.
52. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C, Alaupovic P, Kwong-Fu H, Azen SP. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: A randomized controlled clinical trial. Ann Inten Med 1996; 124:548-56.
53. Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, Descovich G, Ricci G, Rubba P, Mancini M, Gallus G, Bianchi G, D'Alo G, Ventura A. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: The carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 101:627-34.
54. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, White H. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the LIPID atherosclerosis Sub-study. LIPID Trial Research Group. Circulation 1998; 97:1784-90.
55. Smilde TJ, van den Berkmortel FW, Wollersheim H, van Langen H, Kastelein JJ, Stalenhoef AF. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolemia. Eur J Clin Invest 2000; 30:473-80.
56. Ubels FL, Muntinga JH, van Doormaal JJ, Reitsma WD, Smit AJ. Effects of initial and long-term lipid-lowering therapy on vascular wall characteristics. Atherosclerosis 2001; 154:155-61.
57. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effects of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001; 357 577-81.
58. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid initima-media thickness: Main results from the b-blocker cholesterol-lowering asymptomatic plaque study (BCAPS). Circulation 2001; 103:1721-6.
59. Youssef F, Seifalian AM, Jagroop IA, Myint F, Baker D, Mikhailidis DP, Hamilton G. The early effect of lipidlowering treatment on carotid and femoral intimamedia thickness (IMT). Eur J Vasc Endovasc Surg 2002; 23:358-64.
60. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106:2055-60.
61. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. J Am Coll Cardiol 2002; 39:610-16.
62. Nolting PR, de Groot E, Zwinderman AH, Buirma RJ, Trip MD, Kastelein JJ. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia. Arch Intern Med 2003; 163 1837-41.
63. Beishuizen ED, van de Ree MA, Jukema JW, Tamsma JT, van der Vijver JC, Meinders AE, Putter H, Huisman MV. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2004; 27:2887-92.
64. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, Sijbrands EJ, Kastelein JJ. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. JAMA 2004; 292 331-7.
65. van Tits LJ, Smilde TJ, van Wissen S, de Graaf J, Kastelein JJ, Stalenhoef AF. Effects of atrovastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized lowdensity lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J Invest Med 2004; 52:177-84.
66. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A doubleblind, placebo-controlled study of extended release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512-17.
67. Asselbergs FW, van Roon AM, Hillege HL, de Jong PE, Gans RO, Smit AJ, van Gilst WH; PREVEND IT Investigators. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Stroke 2005; 36:649-53.
68. Reid JA, Wolsley C, Lau LL, Hannon RJ, Lee B, Young IS, Soong CV. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. Eur J Vasc Endovasc Surg 2005; 30:464-8.
69. Amarenco P, labreuche, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-analysis. Stroke 2004; 35:2902-9.
70. Mead GE, Lewis SC, Wardlaw JM. Variability in Doppler ultrasound influences referral of patients for carotid surgery. Eur J Ultrasound 2000; 12:137-43.
71. Zanchetti A. The antiatherogenic effects of antihypertensive treatment: trials completed and ongoing. Curr Hypertens Rep 2001; 3 350-9.
72. Bots ML, Hofman A, Grobbee DE. Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke 1997; 28:2442-7.
73. Trogan E, Fayad ZA, Itskovich VV, Aguinaldo JG, Mani V, Fallon JT, Chereshnev I, Fisher EA. Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detected lesion regression after correction of dyslipidemia. Arterioscler Thromb Vasc Biol 2004; 24:1714-19.
74. Corti R. Noninvasive imaging of atherosclerotic vessels by MRI for clinical assessment of the effectiveness of therapy. Pharmacol Ther 2006; 110:57-70.
75. Takaya N, Cai J, Ferguson MS, Yarnykh VL, Chu B, Saam T, Polissar NL, Sherwood J, Cury RC, Anders RJ, Broschat KO, Hinton D, Furie KL, Hatsukami TS, Yuan C. Intra- and interreader reproducibility of magnetic resonance imaging for quantifying the lipid-rich necrotic core is improved with gadolinium contrast enhancement. J Magn Reson Imaging 2006; 24:203-10.
76. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, Weinberger J, Wentzel J, Mizsei G, Mercuri M, Badimon JJ. Lipid lowering by simvastatin induced regression of human atherosclerosis lesions: Two years follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002; 106:2884-7.
77. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316:1371-5.
78. Lima JA, Desai MY, Steen H, Warren WP, Gautam S, Lai S. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 2004; 110 2336-41.
79. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001; 103:926-33.
80. Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, Descovich G, Ricci G, Rubba P, Mancini M, Gallus G, Bianchi G, D'Alo G, Ventura A. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 191:627-34.
81. Takagi T, Yoshida K, Akasaka T, Hozumi T, Morioka S, Yoshikawa J. Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin. Am J Cardiol 1997; 79:1673-7.
82. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF, Muntwyler J, Viles-Gonzalez JF, Weinberger J, Smith DA, Mizsei G, Badimon JJ. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerosis lesions. J Am Coll Cardiol 2005; 46:106-12.
83. Nicholls SJ, Tuzcu EM, Schoenhagen P, Sipahi I, Crowe T, Kapadia S, Nissen SE. Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/ day) on arterial remodeling at coronary branch points (from the REVERSAL study). Am J Cardiol 2005; 96:1636-9.
84. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-504.
85. Yonemura A, Momiyama Y, Fayad ZA, Ayaori M, Ohmori R, Higashi K, Kihara T, Sawada S, Iwamoto N, Ogura M, Taniguchi H, Kusuhara M, Nagata M, Nakamura H, Tamai S, Ohsuzu F. Effects of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 2005; 45 733-42.
86. Schwartz CJ, Mitchell JR. Observation on localization of arterial plaques. Circ Res 1962; 11:63-73.
87. Chung SM. Safety issues in magnetic resonance imaging. J Neuroophthalmol 2002; 22:35-9.
88. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15:827-32.
89. Hasdai D, Bell MR, Grill DE, Berger PB, Garratt KN, Rihal CS, Hammes LN, Holmes DR Jr. Outcome > or = 10 years after successful percutaneous transluminal coronary angioplasty. Am J Cardiol 1997; 79 1005-11.
90. Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. Am Heart J 2001; 141:375-82.
91. Grundy SM. Coronary plaque as a replacement for age as a risk factor in global risk assessment. Am J Cardiol 2001; 88:8-11E.
92. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998; 339 1972-8.
93. Raggi P. The use of electron-beam computed tomography as a tool for primary prevention. Am J Cardiol 2001; 88:28-32.
94. Achenbach S, Giesler T, Ropers D, Ulzheimer S, Derlien H, Schulte C, Wenkel E, Moshage W, Bautz W, Daniel WG, Kalender WA, Baum U. Detection of coronary artery stenoses by contrast-enhanced, retrospectively electrocardiographically-gated, multislice spiral computed tomography. Circulation 2001; 103:2535-8.
95. Nieman K, Oudkerk M, Rensing BJ, van Ooijen P, Munne A, van Geuns RJ, de Feyter PJ. Coronary angiography with multi-slice computed tomography. Lancet 2001; 357:599-603.
96. Schuijf JD, Bax JJ, Shaw LJ, de Roos A, Lamb HJ, van der Wall EE, Wijns W. Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary cangiography. Am Heart J 2006; 151:404-11.